ClearPoint Neuro, Inc. (NASDAQ: CLPT) announced it received a Medical Device License from Health Canada for its Neuro Navigation System. The approval covers both ClearPoint MRI-guidance and iCT-guidance workflows in Canada.

The navigation system clearance builds on the company's previously announced therapy delivery product clearance for the SmartFlow Neuro Cannula received in October 2025. The combined approvals enable Canadian neurosurgery centers to use ClearPoint's image-guidance workflow and therapy delivery platform.

The approval allows the company's biopharma partners to operate Canadian clinical trial and commercial sites using the same platform and workflow used in the United States. Canada joins ClearPoint's 34-country regulatory network for therapy delivery.

"With today's navigation clearance, Canada is now fully integrated into ClearPoint's global regulatory and clinical infrastructure," said Mary McNamara-Cullinane, Senior Vice President of Regulatory Affairs at ClearPoint Neuro.

The company stated that having both navigation and delivery components cleared in Canada allows biopharma sponsors to design Canadian trial sites with workflow consistency. ClearPoint Neuro develops navigation systems for brain and spine procedures and provides services for controlled drug and device delivery.

The company's flagship ClearPoint Neuro Navigation System has FDA clearance and CE marking. ClearPoint Neuro works with healthcare centers across North America, Europe, Asia, and South America, and partners with pharmaceutical companies and research organizations for central nervous system therapeutic delivery.